<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002833</url>
  </required_header>
  <id_info>
    <org_study_id>DM94-078</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-94078</secondary_id>
    <secondary_id>NCI-G96-1001</secondary_id>
    <secondary_id>CDR0000065035</secondary_id>
    <nct_id>NCT00002833</nct_id>
  </id_info>
  <brief_title>Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia</brief_title>
  <official_title>Use of G-CSF Stimulated HLA-Identical Allogeneic Peripheral Blood Stem Cells for Patients With High Risk Acute Myelogenous Leukemia or CML in Blast Crisis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation
      may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.
      Colony stimulating factors such as filgrastim may increase the number of immune cells found
      in bone marrow or peripheral blood and may help a person's immune system recover from the
      side effects of chemotherapy.

      PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation
      plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the toxic effects and feasibility of using filgrastim in promoting
      hematopoietic recovery and leukemia control after intensive but nonmyeloablative salvage
      chemotherapy. II. Determine the engraftment kinetics and degree of chimerism achievable.

      OUTLINE: The trial will have 2 patient groups. Patients not in remission are assigned to
      group 1, while patients in remission are assigned to group 2. Then, groups are divided into 2
      treatment arms. Patients failing fludarabine therapy receive cytarabine (Ara-C) IV over 2
      hours on days -7, -6, -5, -4 and -3. Beginning 4 hours before the first dose of Ara-C,
      patients receive cladribine (2-chlorodeoxyadenosine; 2-CdA) by continuous infusion for 5
      days. Patients without prior fludarabine therapy receive fludarabine IV over 30 minutes daily
      on days -6, -5, -4 and -3. Ara-C IV begins 4 hours after the beginning of the fludarabine
      infusion and continues for 4 hours. Idarubicin IV is given on days -6, -5 and -4. Donors
      receive filgrastim SC every 12 hours for 2 days prior to stem cell collection. Cells are
      infused on day 0. For GVHD prophylaxis, all patients receive cyclosporine via continuous IV
      infusion. Oral cyclosporine is administered once patients tolerate oral feeding and continued
      for 6 months postinfusion. Then, the dose of cyclosporine is tapered 10% weekly until
      discontinued. Methylprednisolone begins 5 days after infusion and is gradually tapered.

      PROJECTED ACCRUAL: A maximum of 15 patients per arm are likely to be entered in 24 to 36
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1994</start_date>
  <completion_date type="Actual">April 2002</completion_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxic Effects of Peripheral Stem Cell Transplantation + Filgrastim</measure>
    <time_frame>24 - 36 months</time_frame>
    <description>Effectiveness as determined by toxic effects and feasibility of using filgrastim in promoting hematopoietic recovery and leukemia control after intensive but nonmyeloablative salvage chemotherapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1A - With or Without Remission + Failing Fludarabine therapy:
Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3 with Cladribine continuous infusion for 5 days, beginning 4 hours before Ara-C first dose. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1B: With or Without Remission, No previous Fludara Therapy
Fludarabine IV over 30 minutes daily on days -6, -5, -4 and -3. Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Donors receive Filgrastim SC (Subcutaneously) every 12 hours for 2 days prior to stem cell collection.</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 1B</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Continuous infusion for 5 days, beginning 4 hours before Ara-C first dose.</description>
    <arm_group_label>Group 1A</arm_group_label>
    <other_name>Leustatin</other_name>
    <other_name>2-CdA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>For GVHD prophylaxis, cyclosporine via continuous IV infusion. Oral cyclosporine administered once tolerating oral feeding and continued for 6 months postinfusion. Then dose tapered 10% weekly until discontinued.</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 1B</arm_group_label>
    <other_name>Sandimmune</other_name>
    <other_name>CYA</other_name>
    <other_name>Cyclosporin A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine (Ara-C)</intervention_name>
    <description>Group 1A: Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3; Group 1B: Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours.</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 1B</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytosine Arabinosine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>IV over 30 minutes daily on days -6, -5, -4 and -3.</description>
    <arm_group_label>Group 1B</arm_group_label>
    <other_name>Fludara</other_name>
    <other_name>Fludarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>IV Days -6, -5 and -4.</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 1B</arm_group_label>
    <other_name>Idamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Begins 5 days after infusion and is gradually tapered.</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 1B</arm_group_label>
    <other_name>Depo-Medrol</other_name>
    <other_name>Medrol</other_name>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Cell infusion Day 0.</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 1B</arm_group_label>
    <other_name>PBSCT</other_name>
    <other_name>Stem Cell Transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Acute leukemia with poor risk cytogenetic features (-5,-7, +8) in
        first complete remission Poor risk myelodysplasia Refractory anemia with excess blasts
        (RAEB) RAEB in transformation (RAEB-T) Chronic myelomonocytic leukemia (CMML) Chronic
        myelogenous leukemia (CML) in late chronic phase Acute leukemia with greater than first
        complete remission or transformed CML or CMML

        PATIENT CHARACTERISTICS: Age: 55 to 65 65 to 70 (at the discretion of study chairperson on
        basis of performance status) 55 and under (if declined for conventional high dose
        chemotherapy due to concurrent medical conditions (i.e. ejection fraction less than 50,
        FEV1, FVC, or DLCO less than 50%, abnormal LFTs) Performance status: Zubrod less than 2
        Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 3
        mg/dL Renal: Serum creatinine less than 2 mg/dL Cardiovascular: Ejection fraction greater
        than 40% per MUGA scan Pulmonary: Not specified Other: No active uncontrolled infection HLA
        compatible donor capable of donating stem cells via apheresis

        PRIOR CONCURRENT THERAPY: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Giralt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 29, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2004</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>graft versus host disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

